Disclaimer · the source of content originated from an external provide and placement with press releases may or may not have been paid-for. Use at your own risk.
Stocks in play: Knight Therapeutics Inc
Announced today that its Colombian affiliate, Biotoscana Farma S.A. has obtained INVIMA approval for Halaven® (eribulin) injection. Halaven® (eribulin) injection is indicated for the treatment of adult patients with locally advanced or metastatic breast cancer which has continued to spread after at least two previous treatment for advanced cancer. Knight Therapeutics Inc shares T.GUD are trading up $0.03 at $5.29.